Mucins as potential biomarkers for early detection of cancer
Simple Summary Early cancer detection is a challenge in treating cancer patients.
Remarkably, carcinomas of the breast, lung, liver, pancreas, ovary, and colon contribute to …
Remarkably, carcinomas of the breast, lung, liver, pancreas, ovary, and colon contribute to …
Antibody-based approaches to target pancreatic tumours
M Sorbara, P Cordelier, N Bery - Antibodies, 2022 - mdpi.com
Pancreatic cancer is an aggressive cancer with a dismal prognosis. This is due to the
difficulty to detect the disease at an early and curable stage. In addition, only limited …
difficulty to detect the disease at an early and curable stage. In addition, only limited …
Effect of a MUC5AC antibody (NPC-1C) administered with second-line gemcitabine and nab-paclitaxel on the survival of patients with advanced pancreatic ductal …
BM Huffman, AB Mallick, NK Horick… - JAMA network …, 2023 - jamanetwork.com
Importance Treatment options are limited for patients with advanced pancreatic ductal
adenocarcinoma (PDAC) beyond first-line 5-fluorouracil, leucovorin, irinotecan, and …
adenocarcinoma (PDAC) beyond first-line 5-fluorouracil, leucovorin, irinotecan, and …
胆道菌群导致原发性肝内胆管结石形成机理的研究进展
任江平， 邱锦飞， 邹杨， 蔡晓蓓， 徐承雷， 李江 - 临床肝胆病杂志, 2022 - lcgdbzz.org
原发性肝内胆管结石(PIS) 是我国西南地区高发和难治性疾病, 在初始治疗后,
部分患者仍需要再次甚至多次手术. 近年来有大量研究发现部分特异性菌群能在肝内胆管定植 …
部分患者仍需要再次甚至多次手术. 近年来有大量研究发现部分特异性菌群能在肝内胆管定植 …
Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma
Mucin MUC4 is an aberrantly expressed oncogene in pancreatic ductal adenocarcinoma
(PDAC), yet no pharmacological inhibitors have been identified to target MUC4. Here, we …
(PDAC), yet no pharmacological inhibitors have been identified to target MUC4. Here, we …
Clinical applications of classical and novel biological markers of pancreatic cancer
L Pekarek, O Fraile-Martinez, C Garcia-Montero… - Cancers, 2022 - mdpi.com
Simple Summary Pancreatic cancer is one of the most heterogeneous and aggressive
tumours that exist. The median survival of diagnosed patients is limited. For all these …
tumours that exist. The median survival of diagnosed patients is limited. For all these …
[HTML][HTML] Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes
A Manne, A Esnakula, A Sheel, A Sara… - International journal of …, 2024 - mdpi.com
Neoadjuvant therapy (NAT) for early-stage pancreatic ductal adenocarcinoma (PDA) has
recently gained prominence. We investigated the clinical significance of mucin 5 AC …
recently gained prominence. We investigated the clinical significance of mucin 5 AC …
[HTML][HTML] Advancements in Early Detection and Screening Strategies for Pancreatic Cancer: From Genetic Susceptibility to Novel Biomarkers
Pancreatic cancer is a rare but lethal cancer due to its biologically aggressive nature,
advanced stage at the time of diagnosis, and poor response to oncologic therapies. The risk …
advanced stage at the time of diagnosis, and poor response to oncologic therapies. The risk …
Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence
Mucin 5AC (MUC5AC) glycoprotein plays a crucial role in carcinogenesis and drug
sensitivity in pancreatic ductal adenocarcinoma (PDAC), both individually and in …
sensitivity in pancreatic ductal adenocarcinoma (PDAC), both individually and in …
Earlier Diagnosis of Pancreatic Cancer: Is It Possible?
T Koltai - Cancers, 2023 - mdpi.com
Simple Summary Pancreatic cancer incidence is increasing yearly. The reasons are not well
known. Unfortunately, this is one of the least treatable cancers. Standard chemotherapy …
known. Unfortunately, this is one of the least treatable cancers. Standard chemotherapy …